BioCryst Pharmaceuticals heads into the final week of June with a striking divergence: short interest is climbing to a one-month high while options traders have swung to their most bullish posture in at least a year.
The short interest story dominates this week's setup. At 20.4% of free float, the short position is meaningful and growing — shares short jumped 13% in a single session on June 25, lifting the 30-day pace of accumulation to roughly 10%. That is a significant rebuild for a name already carrying one of the heavier short loads in small-cap biotech. The ORTEX short score has climbed to 68.4, up from 63.6 two weeks ago, tracking the directional shift. Yet the borrow market is not flashing stress. Cost to borrow has collapsed from around 4% in late May to just under 1% — a 74% weekly drop — signalling the lending pool remains well-supplied. Availability is running at 385%, meaning there are roughly 3.8 shares available to borrow for every one already borrowed. That is tighter than the 600%-plus readings from early June, but still loose enough that new short positions can be opened cheaply. The overall borrow picture looks like fresh directional conviction rather than a squeeze in the making.
Options tell the opposite story. Traders are more bullish on BCRX than at any point in the past year — the put/call ratio has dropped to 0.10, more than 2.5 standard deviations below its 20-day average of 0.23, and near the 52-week floor of 0.097 printed just one session earlier. That is an extreme skew toward calls, meaning participants in the options market are positioned for upside rather than protection. The 11% weekly and 17% monthly gain in the underlying — taking BCRX to $9.94 — gives those call holders momentum on their side.
The Street remains constructive on balance, though recent analyst data is now nearly seven weeks stale (last changes reported around the Q1 earnings print in early May). At that point, the direction was mixed: Citizens raised its target to $28 while maintaining an Outperform, while Wedbush and Needham trimmed targets modestly. The consensus price target of $21.50 implies roughly 116% upside from current levels, though that gap reflects both genuine conviction and the stock's significant de-rating over the past year. Bulls anchor their case on Orladeyo's commercial trajectory, the Neopharmed Gentili licensing deal as non-dilutive capital, and maintained 2026 guidance despite a pediatric manufacturing hiccup. Bears point to ongoing net losses — a $121 million net loss last quarter — rising competition in HAE, and balance-sheet stress visible in the negative EV/EBITDA and an earnings yield factor score near the bottom of the universe. EPS momentum scores are genuinely encouraging at the 68th and 76th percentiles over 30 and 90 days respectively, though that sits alongside an EPS surprise rank in the 1st percentile — the company has a habit of missing estimates on the bottom line.
Institutional ownership shows several active biotech specialists still committed. Deerfield added 697,000 shares through March, Perceptive Advisors added over four million, and Vestal Point Capital initiated or expanded to 7 million shares. BlackRock and State Street both added through May. Insider flow tilts negative — net selling of roughly $5.2 million over the past 90 days — though most transactions look like routine sales from the CLO and a single director block trade, rather than the kind of concentrated executive exit that would raise flags.
The next hard catalyst is an August 5 earnings print. The most recent Q1 result produced a mild 1.4% one-day decline, followed by a 6% five-day recovery. The prior Q4 print moved the stock down on both time horizons. With the short score rising, the short base at a month-high, and call positioning near a 52-week extreme, the August 5 release will be the test of which camp — the rebuilding shorts or the aggressively bullish options traders — had the right read.
See the live data behind this article on ORTEX.
Open BCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
